In vitro activity of tebipenem and comparator agents against bacterial pathogens isolated from patients with cancer.
Bahgat Z GergesJoel RosenblattSamuel A Shelburne IiiAnne-Marie ChaftariRay HachemIssam I RaadPublished in: JAC-antimicrobial resistance (2023)
Oral tebipenem has promising activity against clinically significant bacterial pathogens isolated from patients with cancer. Further clinical evaluation of tebipenem for the treatment of bacterial infections in patients with cancer is warranted.